Dyadic International (DYAI) Stock Price, News & Analysis

Company Overview

Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally. It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health. The company offers DYAI-100, SARS-CoV-2-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial to demonstrate the safety in humans of a protein produced using the C1 platform. It has also developed the Dapibus thermophilic, a filamentous fungal-based microbial protein production platform to enable the development and large-scale manufacture of cost-effective proteins, metabolites, and other biologic products for use in non-pharmaceutical applications, including food, nutrition, and wellness. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; license agreement with South Africa's Rubic One Health; Joint Development Agreement with a Global Food Ingredient Company; and sub-license agreement with Abic Biological Laboratories Ltd., Alphazyme, LLC, and Abic Biological Laboratories Ltd. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.

Key Stats

• Today's Range: $1.29 to $1.45
• 50-Day Range: $1.33 to $1.69
• 52-Week Range: $0.93 to $2.67
• Volume: 74,475 shs
• Average Volume: 69,353 shs
• Market Capitalization: $39.95 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $6.00
• Consensus Rating: Buy

Dyadic International Stock Analysis - MarketRank™

Dyadic International scored higher than 46% of companies evaluated by MarketBeat, and ranked 539th out of 941 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Dyadic International has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Dyadic International has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Dyadic International are expected to decrease in the coming year, from ($0.18) to ($0.19) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Dyadic International is -5.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Dyadic International is -5.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Dyadic International has a P/B Ratio of 6.75. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.47% of the float of Dyadic International has been sold short.

Short Interest Ratio / Days to Cover

Dyadic International has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Dyadic International has recently decreased by 0.41%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Dyadic International does not currently pay a dividend.

Dividend Growth

Dyadic International does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.47% of the float of Dyadic International has been sold short.

Short Interest Ratio / Days to Cover

Dyadic International has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Dyadic International has recently decreased by 0.41%, indicating that investor sentiment is improving.

News and Social Media

• Score: 1.8 / 5
• News Sentiment: 0.17

News Sentiment

Dyadic International has a news sentiment score of 0.17. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.78 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 8 news articles for Dyadic International this week, compared to 1 article on an average week.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Dyadic International insiders have not sold or bought any company stock.

Percentage Held by Insiders

28.80% of the stock of Dyadic International is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 27.95% of the stock of Dyadic International is held by institutions.

DYAI Stock Analysis - Frequently Asked Questions

How have DYAI shares performed this year?

Dyadic International's stock was trading at $1.75 at the beginning of the year. Since then, DYAI shares have decreased by 22.9% and is now trading at $1.35.
View the best growth stocks for 2025 here.

How were Dyadic International's earnings last quarter?

Dyadic International, Inc. (NASDAQ:DYAI) posted its quarterly earnings results on Wednesday, March, 26th. The biotechnology company reported ($0.05) EPS for the quarter, missing the consensus estimate of ($0.04) by $0.01. The biotechnology company had revenue of $0.82 million for the quarter, compared to analysts' expectations of $1.60 million. Dyadic International had a negative net margin of 188.09% and a negative trailing twelve-month return on equity of 149.16%.

Who are Dyadic International's major shareholders?

Dyadic International's top institutional shareholders include Truist Financial Corp (0.84%), Inlet Private Wealth LLC (0.10%), Bank of America Corp DE (0.09%) and Jane Street Group LLC (0.09%).
View institutional ownership trends.

How do I buy shares of Dyadic International?

Shares of DYAI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Dyadic International own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Dyadic International investors own include Pfizer (PFE), Enbridge (ENB), Meta Platforms (META), Silvercorp Metals (SVM), Endeavour Silver (EXK), Hecla Mining (HL) and Advanced Micro Devices (AMD).

Company Calendar

• Last Earnings: 3/26/2025
• Today: 3/27/2025
• Next Earnings (Estimated): 5/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:DYAI
• CIK: 1213809
• Web: www.dyadic.com
• Phone: (561) 743-8333
• Fax: 561-743-8343
• Employees: 7
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $6.00
• High Stock Price Target: $6.00
• Low Stock Price Target: $6.00
• Potential Upside/Downside: +344.4%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.23)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-6,800,000.00
• Net Margins: -188.09%
• Pretax Margin: -188.06%
• Return on Equity: -149.16%
• Return on Assets: -59.81%

Debt

• Debt-to-Equity Ratio: 1.54
• Current Ratio: 5.15
• Quick Ratio: 5.15

Sales & Book Value

• Annual Sales: $3.36 million
• Price / Sales: 11.87
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.20 per share
• Price / Book: 6.75

Miscellaneous

• Outstanding Shares: 29,589,000
• Free Float: 21,067,000
• Market Cap: $39.95 million
• Optionable: Optionable
• Beta: 0.95